Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  Biliary Tract Diseases

  Free Subscription

Articles published in Hepatology

Retrieve available abstracts of 207 articles:
HTML format

Single Articles

    November 2023
  1. GHOSH S, Devereaux MW, Liu C, Sokol RJ, et al
    LRH-1 agonist DLPC through STAT6 promotes macrophage polarization and prevents parenteral nutrition associated cholestasis in mice.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000690.
    PubMed     Abstract available

  2. GEHL V, O'Rourke CJ, Andersen JB
    Immunogenomics of cholangiocarcinoma.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000688.
    PubMed     Abstract available

  3. LIU ZP, Sun XH, Yu C, Yin XY, et al
    Letter to the Editor: How to define the futile outcome in patients undergoing surgery for perihilar cholangiocarcinoma?
    Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000651.

  4. NIKNEJAD N, Fox D, Burwinkel JL, Zarrin-Khameh N, et al
    ASO silencing of a glycosyltransferase, Poglut1 , improves the liver phenotypes in mouse models of Alagille syndrome.
    Hepatology. 2023;78:1337-1351.
    PubMed     Abstract available

  5. YANG F, Hilakivi-Clarke L, Shaha A, Wang Y, et al
    Metabolic reprogramming and its clinical implication for liver cancer.
    Hepatology. 2023;78:1602-1624.
    PubMed     Abstract available

    October 2023
  6. RATTI F, Marino R, Groot Koerkamp B, Aldrighetti L, et al
    Reply: "How to define the futile outcome in patients undergoing surgery for perihilar cholangiocarcinoma".
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000659.

  7. SELLERS ZM, Assis DN, Paranjape SM, Sathe M, et al
    Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations.
    Hepatology. 2023 Oct 26. doi: 10.1097/HEP.0000000000000646.
    PubMed     Abstract available

  8. HU YF, Ma WJ, Jin YW, Li FY, et al
    Adjuvant chemotherapy for resected biliary tract cancers: A fluorouracil-based scheme beats out a gemcitabine-based scheme for the win.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000634.

  9. Erratum: Modulation of the tryptophan hydroxylase 1/monoamine oxidase-A/5-hydroxytryptamine/5-hydroxytryptamine receptor 2A/2B/2C axis regulates biliary proliferation and liver fibrosis during cholestasis.
    Hepatology. 2023;78:E86.

    September 2023
  10. GELLERT-KRISTENSEN H, Bojesen SE, Tybjaerg-Hansen A, Stender S, et al
    Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000608.
    PubMed     Abstract available

  11. ZHUANG Y, Ortega-Ribera M, Thevkar Nagesh P, Joshi R, et al
    Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000611.
    PubMed     Abstract available

    August 2023
  12. PEISELER M, Tacke F
    Bile duct-associated macrophages enter the spotlight in inflammatory cholestatic liver disease.
    Hepatology. 2023 Aug 22. doi: 10.1097/HEP.0000000000000576.

  13. RATTI F, Marino R, Olthof PB, Pratschke J, et al
    Predicting futility of upfront surgery in perihilar cholangiocarcinoma: Machine learning analytics model to optimize treatment allocation.
    Hepatology. 2023 Aug 3. doi: 10.1097/HEP.0000000000000554.
    PubMed     Abstract available

  14. DE MUYNCK K, Heyerick L, De Ponti FF, Vanderborght B, et al
    Osteopontin characterizes bile duct associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis.
    Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000557.
    PubMed     Abstract available

  15. BOWLUS CL, Levy C
    Optimizing treatment of primary biliary cholangitis: Is good, good enough?
    Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000556.

    July 2023
  16. ZHAO L, Liu J, Li K, Zhang C, et al
    PTPN9 dephosphorylates FGFR2pY656/657 via interaction with ACAP1 and ameliorates pemigatinib effect in cholangiocarcinoma.
    Hepatology. 2023 Jul 27. doi: 10.1097/HEP.0000000000000552.
    PubMed     Abstract available

  17. LI Y, Li B, Xiao X, Qian Q, et al
    Itaconate inhibits CD103+ TRM cells and alleviates hepatobiliary injury in mouse models of primary sclerosing cholangitis.
    Hepatology. 2023 Jul 26. doi: 10.1097/HEP.0000000000000549.
    PubMed     Abstract available

  18. EDELINE J, Bridgewater J, Campillo-Gimenez B, Neveu E, et al
    Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials.
    Hepatology. 2023 Jul 25. doi: 10.1097/HEP.0000000000000544.
    PubMed     Abstract available

  19. Retraction: Altered store operated calcium entry increases cyclic 3',5'-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes.
    Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000484.

  20. JEONG H, Yoo C
    Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial - author's reply.
    Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000535.

  21. HU YF, Gu HF, Jin YW, Li FY, et al
    Letter to the Editor: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.
    Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000532.

    June 2023
  22. SOKOL RJ, Gonzales EM, Kamath BM, Baker A, et al
    Predictors of 6-year event-free survival in alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor.
    Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000502.
    PubMed     Abstract available

  23. EKSER B, Sucu S, Mihaylov P, Emamaullee JA, et al
    Letter to the Editor mucosal gut microbiota in primary sclerosing cholangitis before and after liver transplantation: Are there other challenges?
    Hepatology. 2023 Jun 5. doi: 10.1097/HEP.0000000000000503.

    May 2023
  24. NEJAK-BOWEN K, Monga SP
    Wnt-beta-catenin in hepatobiliary homeostasis, injury, and repair.
    Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000495.
    PubMed     Abstract available

  25. Erratum: IL-6-induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
    Hepatology. 2023 May 15. doi: 10.1097/HEP.0000000000000040.

  26. SHU L, Li X, Liu Z, Li K, et al
    Bile exosomal miR-182/183-5p increases cholangiocarcinoma stemness and progression by targeting HPGD and increasing PGE2 generation.
    Hepatology. 2023 May 5. doi: 10.1097/HEP.0000000000000437.
    PubMed     Abstract available

  27. JEONG H, Kim KP, Jeong JH, Hwang DW, et al
    Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial.
    Hepatology. 2023;77:1540-1549.
    PubMed     Abstract available

  28. FORMAN LM, Sapisochin G, Assis DN, Arrive L, et al
    Reply: Living donor liver transplantation for people with PSC.
    Hepatology. 2023;77:E97-E98.

    April 2023
  29. MACKOWIAK B, Gao B
    Activation of cholangiocyte mTORC1 drives alcohol-induced ductular reaction.
    Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000416.

  30. RUSSI AE, Shivakumar P, Luo Z, Bezerra J, et al
    Plasticity between ILC2 subsets and amphiregulin expression regulate epithelial repair in biliary atresia.
    Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000418.
    PubMed     Abstract available

  31. DANIEL N, Genua F, Jenab M, Mayen AL, et al
    The role of the gut microbiome in the development of hepatobiliary cancers.
    Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000406.
    PubMed     Abstract available

  32. HARTL L, Reiberger T, Trauner M
    Reply: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
    Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000399.

  33. UMAR S, Nadeem A, Nadeem M
    Letter to the editor: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
    Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000398.

  34. HIRSCHFIELD GM, Shiffman ML, Gulamhusein A, Kowdley KV, et al
    Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
    Hepatology. 2023 Apr 6. doi: 10.1097/HEP.0000000000000395.
    PubMed     Abstract available

  35. YOO C, Javle MM, Verdaguer Mata H, de Braud F, et al
    Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000365.
    PubMed     Abstract available

  36. CABALLERO-CAMINO FJ, Rodrigues PM, Wangsell F, Agirre-Lizaso A, et al
    A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multi-organ activity and shows translational relevance to humans.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000376.
    PubMed     Abstract available

  37. SINGH SP, Mondia N
    Letter to the Editor: Much more needed in natural history of Alagille syndrome.
    Hepatology. 2023;77:E78.

    March 2023
  38. HARTMANN P, Schnabl B
    Can a mucosal microbiota signature predict disease severity, survival, and disease recurrence in PSC?
    Hepatology. 2023;77:709-711.

    February 2023
  39. MAMMADOV RA, Visseren T, Roest HP, van der Laan LJW, et al
    Letter to Editor: the mucosal gut signature in primary sclerosing cholangitis before and after liver transplantation. is the dysbiosis index really predictive for the recurrence of psc?
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000338.

  40. LI J, Chen J, Lee PMY, Zhang J, et al
    Familial clustering of intrahepatic cholestasis of pregnancy: A nationwide population-based study in Denmark.
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000328.
    PubMed     Abstract available

  41. HOLE MJ, Kaasen Jorgensen K, Holm K, Braadland PR, et al
    Reply: The mucosal gut signature in primary sclerosing cholangitis before and after liver transplantation. Is the dysbiosis index really predictive for the recurrence of PSC?
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000340.

  42. ZHANG J, Lyu Z, Li B, You Z, et al
    P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000317.
    PubMed     Abstract available

  43. KUNDU D, Kennedy L, Zhou T, Ekser B, et al
    p16 INK4A drives non-alcoholic fatty liver disease phenotypes in high fat diet fed mice via biliary e2f1/foxo1/igf-1 signaling.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000307.
    PubMed     Abstract available

  44. WU N, Zhou T, Carpino G, Baiocchi L, et al
    Prolonged administration of a secretin receptor antagonist inhibits biliary senescence and liver fibrosis in Mdr2-/- mice.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000310.
    PubMed     Abstract available

  45. AMENT CE, Steinmann S, Evert K, Pes GM, et al
    Aberrant fucosylation sustains the NOTCH and EGFR/NF-kB pathways and has a prognostic value in human intrahepatic cholangiocarcinoma.
    Hepatology. 2023 Feb 16. doi: 10.1097/HEP.0000000000000322.
    PubMed     Abstract available

  46. VANDRIEL SM, Li LT, She H, Wang JS, et al
    Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study.
    Hepatology. 2023;77:512-529.
    PubMed     Abstract available

  47. HABASH N, Ibrahim SH
    The Global Alagille Alliance study: Redefining the natural history of Alagille syndrome.
    Hepatology. 2023;77:347-349.

    January 2023
  48. ALI AH, Buness CW, Fischer R, Holtmann GJ, et al
    Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis.
    Hepatology. 2023 Jan 30. doi: 10.1097/HEP.0000000000000304.

  49. BOWLUS CL, Arrive L, Bergquist A, Deneau M, et al
    Reply: insurance should cover vancomycin for primary sclerosing cholangitis.
    Hepatology. 2023 Jan 26. doi: 10.1097/HEP.0000000000000305.

  50. LAMARCA A, Edeline J
    Adjuvant treatment for biliary tract tumours: lost in a maze?
    Hepatology. 2023 Jan 23. doi: 10.1097/HEP.0000000000000301.

  51. LI Y, Yang B, Miao H, Liu L, et al
    Nicotinamide N-methyltransferase promotes M2 macrophage polarization by IL6 and MDSC conversion by GM-CSF in gallbladder carcinoma.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000028.
    PubMed     Abstract available

  52. UNALP-ARIDA A, Ruhl CE
    Increasing gallstone disease prevalence and associations with gallbladder and biliary tract mortality in the United States.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000264.
    PubMed     Abstract available

  53. GUILLOT A, Winkler M, Silva Afonso M, Aggarwal A, et al
    Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000270.
    PubMed     Abstract available

  54. SHORT C, Zhong A, Xu J, Mahdi E, et al
    TWEAK/FN14 promotes profibrogenic pathway activation in Prominin-1-expressing hepatic progenitor cells in biliary atresia.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000026.
    PubMed     Abstract available

  55. LEE SH, So J, Shin D
    Hepatocyte-to-cholangiocyte conversion occurs through transdifferentiation independently of proliferation in zebrafish.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000016.
    PubMed     Abstract available

  56. ZHANG L, Pan Q, Zhang L, Xia H, et al
    Runt-related transcription factor-1 ameliorates bile acid-induced hepatic inflammation in cholestasis through JAK/STAT3 signaling.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000041.
    PubMed     Abstract available

  57. HELLEN DJ, Bennett A, Malla S, Klindt C, et al
    Liver-restricted deletion of the biliary atresia candidate gene Pkd1l1 causes bile duct dysmorphogenesis and ciliopathy.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000029.
    PubMed     Abstract available

  58. NYHOLM I, Hukkinen M, Pihlajoki M, Davidson JR, et al
    Serum FGF19 predicts outcomes of Kasai portoenterostomy in biliary atresia.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000048.
    PubMed     Abstract available

  59. MA J, Yang Z, Huang Z, Li L, et al
    Rngtt governs biliary-derived liver regeneration initiation by transcriptional regulation of mTORC1 and Dnmt1 in zebrafish.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000186.
    PubMed     Abstract available

  60. CANTALLOPS VILA P, Ravichandra A, Agirre Lizaso A, Perugorria MJ, et al
    Heterogeneity, crosstalk and targeting of cancer associated fibroblasts in cholangiocarcinoma.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000206.
    PubMed     Abstract available

  61. HEINEMANN M, Adam R, Karam V, Schramm C, et al
    Letter to the Editor: Living donor liver transplantation for people with PSC.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000208.

    September 2022
  62. BORAD MJ, Bai LY, Richards D, Mody K, et al
    Silmitasertib Plus Gemcitabine and Cisplatin First-Line Therapy in Locally Advanced/Metastatic Cholangiocarcinoma: a Phase 1b/2 Study.
    Hepatology. 2022 Sep 24. doi: 10.1002/hep.32804.
    PubMed     Abstract available

  63. HARPAVAT S, Hawthorne K, Setchell KDR, Narvaez Rivas M, et al
    Serum Bile Acids as a New Prognostic Biomarker in Biliary Atresia Following Kasai Portoenterostomy.
    Hepatology. 2022 Sep 21. doi: 10.1002/hep.32800.
    PubMed     Abstract available

  64. BIAGIOLI M, Marchiano S, di Giorgio C, Roselli R, et al
    Combinatorial targeting of GPBAR1 and CYSLTR1 reveals a mechanistic role for bile acids and leukotrienes in drug induced liver injury.
    Hepatology. 2022 Sep 15. doi: 10.1002/hep.32787.
    PubMed     Abstract available

  65. BOWLUS CL, Arrive L, Bergquist A, Deneau M, et al
    AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma.
    Hepatology. 2022 Sep 9. doi: 10.1002/hep.32771.

  66. LEUNG DH, Devaraj S, Goodrich NP, Chen X, et al
    Serum Biomarkers Correlated with Liver Stiffness Assessed in a Multi-center Study of Pediatric Cholestatic Liver Disease.
    Hepatology. 2022 Sep 7. doi: 10.1002/hep.32777.
    PubMed     Abstract available

  67. HOLE MJ, Kaasen Jorgensen K, Holm K, Braadland PR, et al
    A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation.
    Hepatology. 2022 Sep 3. doi: 10.1002/hep.32773.
    PubMed     Abstract available

    August 2022
  68. MAYO MJ
    Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?
    Hepatology. 2022;76:518-531.
    PubMed     Abstract available

  69. ZHANG X, Wang Z, Tang W, Wang X, et al
    Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics.
    Hepatology. 2022;76:317-329.
    PubMed     Abstract available

    July 2022
  70. HEUCKE N, Keitel V
    COVID-19-associated cholangiopathy: What's left after the virus has gone?
    Hepatology. 2022 Jul 13. doi: 10.1002/hep.32668.

  71. HARTL L, Reiberger T, Trauner M
    On the development of secondary sclerosing cholangitis in chronic liver disease patients after COVID-19.
    Hepatology. 2022 Jul 12. doi: 10.1002/hep.32664.

    June 2022
  72. DENG M, Ran P, Chen L, Wang Y, et al
    Proteogenomic Characterization of Cholangiocarcinoma.
    Hepatology. 2022 Jun 18. doi: 10.1002/hep.32624.
    PubMed     Abstract available

  73. Retracted: Posttranslational regulation of polycystin-2 protein expression as a novel mechanism of cholangiocyte reaction and repair from biliary damage.
    Hepatology. 2022 Jun 17. doi: 10.1002/hep.32595.
    PubMed     Abstract available

  74. XU J, Wang Y, Khoshdeli M, Peach M, et al
    IL-31 Levels Correlate with Pruritus in Patients with Cholestatic and Metabolic Liver Diseases and is FXR Responsive in NASH.
    Hepatology. 2022 Jun 10. doi: 10.1002/hep.32599.
    PubMed     Abstract available

    May 2022
  75. HARTL L, Haslinger K, Angerer M, Semmler G, et al
    Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in chronic liver disease patients.
    Hepatology. 2022 May 21. doi: 10.1002/hep.32582.
    PubMed     Abstract available

  76. SMIRNOVA E, Muthiah MD, Narayan N, Siddiqui MS, et al
    Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD.
    Hepatology. 2022 May 13. doi: 10.1002/hep.32568.
    PubMed     Abstract available

    Stromal yin-yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma.
    Hepatology. 2022 May 3. doi: 10.1002/hep.32558.

  78. ZHOU J, Sun Y, Zhang W, Yuan J, et al
    Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis.
    Hepatology. 2022 May 1. doi: 10.1002/hep.32548.
    PubMed     Abstract available

    April 2022
  79. JIANG ST, Zhang L, Xu YY, Lu X, et al
    Letter to the editor: For the core set of bile lipidome and meta-proteome signature, repeatability is the key.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32543.

  80. SHARMA N, Yadav M, Tripathi G, Mathew B, et al
    Response to Letter to the editor: For the core set of bile lipidome and meta-proteome signature, repeatability is the key.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32541.

  81. SHCHEYNIKOV N, Boggs K, Green A, Feranchak AP, et al
    Identification of the Chloride Channel, Leucine-Rich Repeat-Containing Protein 8, subfamily A (LRRC8A), in Mouse Cholangiocytes.
    Hepatology. 2022 Apr 21. doi: 10.1002/hep.32536.
    PubMed     Abstract available

  82. MOHAMAD ZAKI NH, Shiota J, Calder AN, Keeley TM, et al
    C-X-C motif chemokine ligand 1 induced by Hedgehog signaling promotes mouse extrahepatic bile duct repair after acute injury.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32492.
    PubMed     Abstract available

  83. MANDATO C, Vajro P
    Letter to the Editor: The burgeoning field of Progressive Familial Intrahepatic Cholestasis.
    Hepatology. 2022 Apr 5. doi: 10.1002/hep.32489.

    March 2022
  84. SHARMA N, Yadav M, Tripathi G, Mathew B, et al
    Bile multi-omics analysis classifies lipid species and microbial peptides predictive of Carcinoma of Gall bladder.
    Hepatology. 2022 Mar 31. doi: 10.1002/hep.32496.
    PubMed     Abstract available

    Letter to the Editor: Hyperosmolarity during hepatic bile formation:Overlooked significance.
    Hepatology. 2022 Mar 29. doi: 10.1002/hep.32482.

  86. HENGSTLER JG, Oude Elferink R, van de Graaf SF, Drasdo D, et al
    The de-micellization hypothesis of water influx into bile ducts.
    Hepatology. 2022 Mar 28. doi: 10.1002/hep.32485.

  87. WANG T, Xu C, Zhang Z, Wu H, et al
    Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression.
    Hepatology. 2022 Mar 27. doi: 10.1002/hep.32483.
    PubMed     Abstract available

  88. BASS LM, Ye W, Hawthorne K, Leung DH, et al
    The Risk of Variceal Hemorrhage and Pre-Transplant Mortality in Children with Biliary Atresia.
    Hepatology. 2022 Mar 10. doi: 10.1002/hep.32451.
    PubMed     Abstract available

  89. Erratum for Nevi, et al. DCLK1, a putative stem cell marker in human cholangiocarcinoma.
    Hepatology. 2022;75:773.

  90. IBRAHIM SH, Kamath BM, Loomes KM, Karpen SJ, et al
    Cholestatic Liver Diseases of Genetic Etiology: Advances and Controversies.
    Hepatology. 2022 Mar 1. doi: 10.1002/hep.32437.
    PubMed     Abstract available

    February 2022
  91. WU MJ, Shi L, Merritt J, Zhu AX, et al
    Biology of IDH Mutant Cholangiocarcinoma.
    Hepatology. 2022 Feb 28. doi: 10.1002/hep.32424.
    PubMed     Abstract available

  92. ROBERTS SB, Hirschfield GM, Worobetz LJ, Vincent C, et al
    Ethnicity, disease severity and survival in Canadian patients with Primary Biliary Cholangitis.
    Hepatology. 2022 Feb 26. doi: 10.1002/hep.32426.
    PubMed     Abstract available

  93. CHAUDHRY HUR, Hayat A, Ahmad A
    Letter to the Editor: Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study.
    Hepatology. 2022 Feb 19. doi: 10.1002/hep.32416.

  94. JEON Y, Kwon SM, Rhee H, Yoo JE, et al
    Molecular and radio-pathologic spectrum between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Hepatology. 2022 Feb 5. doi: 10.1002/hep.32397.
    PubMed     Abstract available

  95. LUO C, Xin H, Zhou Z, Hu Z, et al
    Tumor-Derived Exosomes Induce Immunosuppressive Macrophages to Foster Intrahepatic Cholangiocarcinoma Progression.
    Hepatology. 2022 Feb 2. doi: 10.1002/hep.32387.
    PubMed     Abstract available

  96. YANG Y, Choi J, Chen Y, Invernizzi P, et al
    E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants.
    Hepatology. 2022;75:266-279.
    PubMed     Abstract available

    January 2022
  97. RUIZ DE GAUNA M, Biancaniello F, Gonzalez-Romero F, Rodrigues PM, et al
    Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids.
    Hepatology. 2022 Jan 14. doi: 10.1002/hep.32344.
    PubMed     Abstract available

    Outside influence: the extrahepatic duct as a source for bile duct regeneration.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32334.

  99. SHIODE Y, Kodama T, Shigeno S, Murai K, et al
    Traf3 inactivation promotes the development of intrahepatic cholangiocarcinoma via NIK-mediated hepatocyte transdifferentiation.
    Hepatology. 2022 Jan 7. doi: 10.1002/hep.32317.
    PubMed     Abstract available

  100. Retracted: Immunoglobulin G4(+) B-cell receptor clones distinguish immunoglobulin G4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies.
    Hepatology. 2022 Jan 7. doi: 10.1002/hep.32246.

    December 2021
  101. PASTOR CM
    Reply to the review <>.
    Hepatology. 2021 Dec 27. doi: 10.1002/hep.32296.

  102. VARTAK N, Hengstler JG
    REPLY TO HEP-21-2202: Analysis and limits of detection of biliary flux.
    Hepatology. 2021 Dec 25. doi: 10.1002/hep.32297.

  103. MASYUK AI, Masyuk TV, Trussoni CE, Pirius NE, et al
    Autophagy Promotes Hepatic Cystogenesis in Polycystic Liver Disease via Depletion of Cholangiocyte Ciliogenic Proteins.
    Hepatology. 2021 Dec 23. doi: 10.1002/hep.32298.
    PubMed     Abstract available

  104. REMETIC J, Ghallab A, Hobloss Z, Brackhagen L, et al
    Loss of bile salt export pump aggravates lipopolysaccharide-induced liver injury in mice due to impaired hepatic endotoxin clearance.
    Hepatology. 2021 Dec 20. doi: 10.1002/hep.32289.
    PubMed     Abstract available

  105. SAPISOCHIN G, Ivanics T, Heimbach J
    Liver Transplantation for intrahepatic cholangiocarcinoma: ready for prime time?
    Hepatology. 2021 Dec 3. doi: 10.1002/hep.32258.
    PubMed     Abstract available

    November 2021
  106. RUBINO JG, Flemming JA
    Menopausal hormone therapy and risk of biliary tract cancers: addressing the ant, not the elephant in the room.
    Hepatology. 2021 Nov 25. doi: 10.1002/hep.32254.
    PubMed     Abstract available

  107. JACKSON SS, Pfeiffer RM, Gabbi C, Anderson L, et al
    Menopausal hormone therapy and risk of biliary tract cancers.
    Hepatology. 2021 Nov 11. doi: 10.1002/hep.32198.
    PubMed     Abstract available

  108. LI H, Lan T, Liu H, Liu C, et al
    IL-6 induced cGGNBP2 encodes a novel protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Nov 10. doi: 10.1002/hep.32232.
    PubMed     Abstract available

  109. WU N, Carpino G, Ceci L, Baiocchi L, et al
    MT1 but not MT2 melatonin receptor knockout decreases biliary damage and liver fibrosis during cholestatic liver injury.
    Hepatology. 2021 Nov 7. doi: 10.1002/hep.32233.
    PubMed     Abstract available

  110. LEE BT, Tana MM, Kahn JA, Dara L, et al
    We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases.
    Hepatology. 2021;74:2876-2887.
    PubMed     Abstract available

    October 2021
  111. ZIMMER CL, Filipovic I, Cornillet M, O'Rourke CJ, et al
    MAIT cell tumor infiltration predicts long-term survival in cholangiocarcinoma.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32222.
    PubMed     Abstract available

  112. KONIGSHOFER P, Hofer BS, Brusilovskaya K, Simbrunner B, et al
    Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32220.
    PubMed     Abstract available

  113. LINDOR KD, Dawson PA, Trauner M
    Alan Hofmann (1931-2021): A Career Well Spent Understanding Bile Acids.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32206.
    PubMed     Abstract available

  114. FAIRFIELD CJ, Drake TM, Pius R, Bretherick AD, et al
    Genome-wide Analysis Identifies Novel Gallstone-susceptibility Loci Including Genes Regulating Gastrointestinal Motility.
    Hepatology. 2021 Oct 15. doi: 10.1002/hep.32199.
    PubMed     Abstract available

  115. GRAHAM JJ, Mukherjee S, Yuksel M, Sanabria Mateos R, et al
    Aberrant hepatic trafficking of gut-derived T-cells is not specific to primary sclerosing cholangitis.
    Hepatology. 2021 Oct 11. doi: 10.1002/hep.32193.
    PubMed     Abstract available

  116. CHEN L, Yang H, Li H, He C, et al
    Novel insights into modifiable risk factors of cholelithiasis: A Mendelian randomization study.
    Hepatology. 2021 Oct 8. doi: 10.1002/hep.32183.
    PubMed     Abstract available

  117. LLEO A, Hirschfield GM
    Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver-Related Mortality Is Higher in Males?
    Hepatology. 2021;74:2307.

  118. MA Y, Su H, Yuksel M, Longhi MS, et al
    Human Leukocyte Antigen Profile Predicts Severity of Autoimmune Liver Disease in Children of European Ancestry.
    Hepatology. 2021;74:2032-2046.
    PubMed     Abstract available

    September 2021
  119. ZHAO C, Lancman JJ, Yang Y, Gates KP, et al
    Intrahepatic cholangiocyte regeneration from an Fgf-dependent extrahepatic progenitor niche in a zebrafish model of Alagille Syndrome.
    Hepatology. 2021 Sep 27. doi: 10.1002/hep.32173.
    PubMed     Abstract available

  120. HUNG HY, Wang CC, Wei JC
    Letter to the Editor: Postdiagnosis aspirin use associated with decreased biliary tract cancer?
    Hepatology. 2021 Sep 23. doi: 10.1002/hep.32170.
    PubMed     Abstract available

  121. VARTAK N, Hengstler JG
    Response to 21-1766: Challenging the dogma of canalicular bile flow.
    Hepatology. 2021 Sep 21. doi: 10.1002/hep.32168.
    PubMed     Abstract available

  122. ZHOU SL, Luo CB, Song CL, Zhou ZJ, et al
    Genomic evolution and the impact of SLIT2 mutation in relapsed intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Sep 20. doi: 10.1002/hep.32164.
    PubMed     Abstract available

  123. JAVITT NB, Boyer JL
    Letter to the Editor: On the Mechanisms of Biliary Flux.
    Hepatology. 2021 Sep 20. doi: 10.1002/hep.32167.
    PubMed     Abstract available

  124. DE JONG IEM, Overi D, Carpino G, Gouw ASH, et al
    Persistent Biliary Hypoxia and Lack of Regeneration Are Key Mechanisms in the Pathogenesis of Post-transplant Non-anastomotic Strictures.
    Hepatology. 2021 Sep 20. doi: 10.1002/hep.32166.
    PubMed     Abstract available

  125. CARAPETO F, Bozorgui B, Shroff RT, Chagani S, et al
    The Immunogenomic Landscape of Resected Intrahepatic Cholangiocarcinoma.
    Hepatology. 2021 Sep 12. doi: 10.1002/hep.32150.
    PubMed     Abstract available

  126. AN J, Kim D, Oh B, Oh YJ, et al
    Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
    Hepatology. 2021 Sep 3. doi: 10.1002/hep.32135.
    PubMed     Abstract available

  127. WANG SS, Tang XT, Lin M, Yuan J, et al
    Perivenous Stellate Cells Are the Main Source of Myofibroblasts and Cancer-Associated Fibroblasts Formed After Chronic Liver Injuries.
    Hepatology. 2021;74:1578-1594.
    PubMed     Abstract available

  128. WANG Y, Hylemon PB, Zhou H
    Long Noncoding RNA H19: A Key Player in Liver Diseases.
    Hepatology. 2021;74:1652-1659.

    August 2021
  129. VEDELD HM, Grimsrud MM, Andresen K, Pharo HD, et al
    Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile.
    Hepatology. 2021 Aug 26. doi: 10.1002/hep.32125.
    PubMed     Abstract available

  130. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
    Primary Biliary Cholangitis: 2021 Practice Guidance Update from the American Association for the Study of Liver Diseases.
    Hepatology. 2021 Aug 24. doi: 10.1002/hep.32117.
    PubMed     Abstract available

  131. ARORA M, Bogenberger JM, Abdelrahman AM, Yonkus J, et al
    Synergistic Combination of Cytotoxic Chemotherapy and Cyclin Dependent Kinase 4/6 Inhibitors in Biliary Tract Cancers.
    Hepatology. 2021 Aug 18. doi: 10.1002/hep.32102.
    PubMed     Abstract available

  132. AMARACHINTHA SP, Mourya R, Ayabe H, Yang L, et al
    Biliary organoids uncover delayed epithelial development and barrier function in biliary atresia.
    Hepatology. 2021 Aug 15. doi: 10.1002/hep.32107.
    PubMed     Abstract available

  133. EL KASMI KC, Ghosh S, Anderson AL, Devereaux MW, et al
    Pharmacologic Activation of Hepatic Farnesoid X Receptor Prevents Parenteral Nutrition Associated Cholestasis in Mice.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32101.
    PubMed     Abstract available

  134. LIN Y, Cai Q, Chen Y, Shi T, et al
    CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma via 5-lipoxygenase.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32099.
    PubMed     Abstract available

  135. ZENG R, Sha W, Leung FW, Chen H, et al
    Letter to the Editor: Proton pump inhibitors and Biliary Tract Cancer Risk: Causality or Reverse Causality?
    Hepatology. 2021 Aug 5. doi: 10.1002/hep.32090.
    PubMed     Abstract available

    July 2021
  136. PANT K, Peixoto E, Richard S, Biswas A, et al
    Histone Deacetylase SIRT1 promotes loss of primary cilia in Cholangiocarcinoma.
    Hepatology. 2021 Jul 29. doi: 10.1002/hep.32080.
    PubMed     Abstract available

  137. CAI P, Mao X, Zhao J, Nie L, et al
    Farnesoid X Receptor is Required for the Redifferentiation of Bi-potential Progenitor Cells during Biliary-Mediated Zebrafish Liver Regeneration.
    Hepatology. 2021 Jul 28. doi: 10.1002/hep.32076.
    PubMed     Abstract available

  138. WADHWANI SI, Gottlieb L, Bucuvalas JC, Lyles C, et al
    Addressing social adversity to improve outcomes for children after liver transplant.
    Hepatology. 2021 Jul 28. doi: 10.1002/hep.32073.
    PubMed     Abstract available

  139. GHOSH S, Devereaux MW, Anderson AL, Gehrke S, et al
    NFkappaB regulation of LRH-1 and ABCG5/8 potentiates phytosterol role in the pathogenesis of parenteral nutrition associated cholestasis.
    Hepatology. 2021 Jul 26. doi: 10.1002/hep.32071.
    PubMed     Abstract available

  140. LOBE C, Vallette M, Arbelaiz A, Gonzalez-Sanchez E, et al
    ZEB1 promotes cholangiocarcinoma progression through tumor dedifferentiation and tumor-stroma paracrine signaling.
    Hepatology. 2021 Jul 23. doi: 10.1002/hep.32069.
    PubMed     Abstract available

  141. ZHANG JW, Yang X, Ding HR, Zhang L, et al
    Is aspirin a drug or just a marker for biliary cancer?
    Hepatology. 2021 Jul 9. doi: 10.1002/hep.32052.
    PubMed     Abstract available

  142. LEE MH, Huang YH, Koshiol J
    Response Letter Regarding Article, "Postdiagnosis aspirin use associated with decreased biliary tract cancer-specific mortality in a large nationwide cohort".
    Hepatology. 2021 Jul 8. doi: 10.1002/hep.32051.
    PubMed     Abstract available

  143. DE GOEIJ FHC, Schlegel A, Muiesan P, Guarrera JV, et al
    Hypothermic oxygenated machine perfusion protects from cholangiopathy in DCD liver transplantation.
    Hepatology. 2021 Jul 7. doi: 10.1002/hep.32044.
    PubMed     Abstract available

  144. WANG H, Song X, Liao H, Wang P, et al
    Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
    Hepatology. 2021;74:248-263.
    PubMed     Abstract available

    June 2021
  145. VARTAK N, Drasdo D, Geisler F, Itoh T, et al
    On the mechanisms of biliary flux.
    Hepatology. 2021 Jun 23. doi: 10.1002/hep.32027.
    PubMed     Abstract available

  146. SHI S, Chen S, Verstegen MMA, Pan Q, et al
    Letter to the Editor: HMGB1 Release is a Newly Identified Driver of Inflammation in the Pathogenesis of Biliary Atresia.
    Hepatology. 2021 Jun 23. doi: 10.1002/hep.32026.
    PubMed     Abstract available

  147. MEADOWS V, Kennedy L, Ekser B, Kyritsi K, et al
    Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis via Farnesoid X Receptor Signaling.
    Hepatology. 2021 Jun 23. doi: 10.1002/hep.32028.
    PubMed     Abstract available

  148. BARRON-MILLAR B, Ogle L, Mells G, Flack S, et al
    The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.32011.
    PubMed     Abstract available

  149. LEE YT, Wang JJ, Luu M, Noureddin M, et al
    Comparison of Clinical Features and Outcomes between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
    Hepatology. 2021 Jun 11. doi: 10.1002/hep.32007.
    PubMed     Abstract available

  150. KYRITSI K, Kennedy L, Meadows V, Hargrove L, et al
    Mast Cells Induce Ductular Reaction Mimicking Liver Injury in Mice Through Mast Cell-Derived Transforming Growth Factor Beta 1 Signaling.
    Hepatology. 2021;73:2397-2410.
    PubMed     Abstract available

    May 2021
  151. LEPORE A, Choy PM, Lee NC, Carella MA, et al
    Phosphorylation and stabilization of PIN1 by JNK promote intrahepatic cholangiocarcinoma growth.
    Hepatology. 2021 May 28. doi: 10.1002/hep.31983.
    PubMed     Abstract available

  152. SUN LY, Hu JY, Liang L, Tong XM, et al
    Letter to the Editor: Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?
    Hepatology. 2021 May 22. doi: 10.1002/hep.31916.
    PubMed     Abstract available

  153. JOHN BV, Deng Y, Martin P, Levy C, et al
    Response to "Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?"
    Hepatology. 2021 May 22. doi: 10.1002/hep.31917.
    PubMed     Abstract available

  154. KAMAL H, Sadr-Azodi O, Engstrand L, Brusselaers N, et al
    Association between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: a Swedish Population-Based Cohort Study.
    Hepatology. 2021 May 21. doi: 10.1002/hep.31914.
    PubMed     Abstract available

  155. MARTINEZ M, Perito ER, Valentino P, Mack CL, et al
    Recurrence of primary sclerosing cholangitis after liver transplant in children: an international observational study.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31911.
    PubMed     Abstract available

  156. JANSSON H, Sparrelid E
    Letter to the Editor: The role of surgery in multiple intrahepatic cholangiocarcinoma should not be dismissed without further analysis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31905.
    PubMed     Abstract available

  157. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Reply to (20-1119.R1) Surgery for advanced intrahepatic cholangiocarcinoma warrants further investigation.
    Hepatology. 2021 May 17. doi: 10.1002/hep.31904.
    PubMed     Abstract available

  158. GENTILINI A, Lori G, Caligiuri A, Raggi C, et al
    Extracellular signal-regulated kinase 5 regulates the malignant phenotype of cholangiocarcinoma cells.
    Hepatology. 2021 May 6. doi: 10.1002/hep.31888.
    PubMed     Abstract available

  159. LIAO SF, Koshiol J, Huang YH, Jackson SS, et al
    Postdiagnosis aspirin use associated with decreased biliary tract cancer-specific mortality in a large nationwide cohort.
    Hepatology. 2021 May 3. doi: 10.1002/hep.31879.
    PubMed     Abstract available

  160. VAN DER LAAN LJW, Roos FJM, Verstegen MMA
    Bile Duct Repair in Human Liver Grafts: Effective Cholangiocyte Organoid Engraftment and Plasticity.
    Hepatology. 2021 May 2. doi: 10.1002/hep.31877.
    PubMed     Abstract available

    April 2021
  161. YOON JG, Kim MH, Jang M, Kim H, et al
    Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and PD-1/PD-L1 Blockade Responses.
    Hepatology. 2021 Apr 21. doi: 10.1002/hep.31862.
    PubMed     Abstract available

  162. XU Y, Leng K, Yao Y, Kang P, et al
    A Circular RNA, Cholangiocarcinoma-Associated Circular RNA 1, Contributes to Cholangiocarcinoma Progression, Induces Angiogenesis, and Disrupts Vascular Endothelial Barriers.
    Hepatology. 2021;73:1419-1435.
    PubMed     Abstract available

  163. OSTROUMOV D, Duong S, Wingerath J, Woller N, et al
    Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
    Hepatology. 2021;73:1399-1418.
    PubMed     Abstract available

    March 2021
  164. DI-LUOFFO M, Pirenne S, Saandi T, Loriot A, et al
    A novel mouse model of cholangiocarcinoma uncovers a role for Tensin-4 in tumor progression.
    Hepatology. 2021 Mar 26. doi: 10.1002/hep.31834.
    PubMed     Abstract available

  165. BOERNER T, Drill E, Pak LM, Nguyen B, et al
    Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
    Hepatology. 2021 Mar 25. doi: 10.1002/hep.31829.
    PubMed     Abstract available

  166. LUO X, Campbell NA, He L, O'Brien DR, et al
    SULF2 monoclonal antibody 5D5 suppresses human cholangiocarcinoma xenograft growth via regulation of a SULF2-PDGFRbeta-YAP signaling axis.
    Hepatology. 2021 Mar 18. doi: 10.1002/hep.31817.
    PubMed     Abstract available

  167. WADA Y, Shimada M, Yamamura K, Toshima T, et al
    A transcriptomic signature for risk-stratification and recurrence prediction in intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31803.
    PubMed     Abstract available

  168. CRISTOFERI L, Calvaruso V, Overi D, Vigano M, et al
    Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naive patients with Primary Biliary Cholangitis: a dual cut-off approach.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31810.
    PubMed     Abstract available

  169. KENDRE G, Marhenke S, Lorz G, Becker D, et al
    The co-mutational spectrum determines the therapeutic response in murine FGFR2 fusion - driven cholangiocarcinoma.
    Hepatology. 2021 Mar 11. doi: 10.1002/hep.31799.
    PubMed     Abstract available

  170. VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
    Impact of Genotype, Serum Bile Acids, and Surgical Biliary Diversion on Native Liver Survival in FIC1 Deficiency.
    Hepatology. 2021 Mar 5. doi: 10.1002/hep.31787.
    PubMed     Abstract available

  171. ZHOU Y, Chen Y, Zhang X, Xu Q, et al
    Brg1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion.
    Hepatology. 2021 Mar 2. doi: 10.1002/hep.31780.
    PubMed     Abstract available

    February 2021
  172. CHIU M, Garabon J, Chen L, Karp N, et al
    Mevalonic Aciduria Associated with Intrahepatic Bile Duct Paucity.
    Hepatology. 2021 Feb 27. doi: 10.1002/hep.31778.
    PubMed     Abstract available

  173. JOHNSON KM, Fischer RT, Holtmann GJ, Shah A, et al
    Letter to the editor: Oral vancomycin versus no therapy for pediatric primary sclerosing cholangitis.
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31764.
    PubMed     Abstract available

  174. SHIOTA J, Samuelson LC, Razumilava N
    Hepatobiliary organoids and their applications for studies of liver health and disease: are we there yet?
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31772.
    PubMed     Abstract available

  175. JOHN BV, Aitcheson G, Schwartz KB, Shabbir Khakoo N, et al
    Male Gender is Associated with Higher Rates of Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis.
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31776.
    PubMed     Abstract available

  176. DAT NQ, Thuy LTT, Hieu VN, Hai H, et al
    6His-tagged Recombinant Human Cytoglobin Deactivates Hepatic Stellate Cells and Inhibits Liver Fibrosis by Scavenging Reactive Oxygen Species.
    Hepatology. 2021 Feb 11. doi: 10.1002/hep.31752.
    PubMed     Abstract available

  177. MOHANTY SK, Donnelly B, Temple H, Ortiz-Perez A, et al
    HMGB1 release by cholangiocytes governs biliary atresia pathogenesis and correlates with increases in afflicted infants.
    Hepatology. 2021 Feb 8. doi: 10.1002/hep.31745.
    PubMed     Abstract available

  178. JAVITT NB
    Letter to the Editor: Intravital dynamic and correlative imaging reveals diffusion-dominated canalicular and flow-augmented ductular bile flux.
    Hepatology. 2021 Feb 8. doi: 10.1002/hep.31746.
    PubMed     Abstract available

  179. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Reply to "Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?"; multiple primaries vs liver metastases.
    Hepatology. 2021 Feb 7. doi: 10.1002/hep.31740.
    PubMed     Abstract available

  180. ZHANG XF, Lv Y, Pawlik TM
    Letter to the editor: Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?
    Hepatology. 2021 Feb 6. doi: 10.1002/hep.31741.
    PubMed     Abstract available

  181. NASSER-GHODSI N, Mara K, Watt KD
    De novo Colorectal and Pancreatic Cancer in Liver Transplant Recipients: Identifying the Higher Risk Populations.
    Hepatology. 2021 Feb 5. doi: 10.1002/hep.31731.
    PubMed     Abstract available

    January 2021
  182. ITOH A, Adams D, Huang W, Wu Y, et al
    Enoxacin upregulates microRNA biogenesis and downregulates cytotoxic CD8 T cell function in autoimmune cholangitis.
    Hepatology. 2021 Jan 19. doi: 10.1002/hep.31724.
    PubMed     Abstract available

  183. LI J, Ye X, He S
    Letter to the Editor: Imaging monitoring of primary sclerosing cholangitis patients.
    Hepatology. 2021 Jan 11. doi: 10.1002/hep.31709.
    PubMed     Abstract available

  184. ASSIS DN, Levy C
    Oral Vancomycin or Ursodeoxycholic acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials.
    Hepatology. 2021 Jan 5. doi: 10.1002/hep.31702.
    PubMed     Abstract available

  185. FENG GS, Hanley KL, Liang Y, Lin X, et al
    Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies.
    Hepatology. 2021;73 Suppl 1:104-114.
    PubMed     Abstract available

  186. RIZVI S, Wang J, El-Khoueiry AB
    Liver Cancer Immunity.
    Hepatology. 2021;73 Suppl 1:86-103.

  187. LU X, Paliogiannis P, Calvisi DF, Chen X, et al
    Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies.
    Hepatology. 2021;73 Suppl 1:49-61.
    PubMed     Abstract available

    December 2020
  188. KOUKOULIOTI E, Ziagaki A, Weber SN, Lammert F, et al
    Long-term colestyramine treatment prevents cholestatic attacks in refractory benign recurrent intrahepatic cholestasis type 1 disease.
    Hepatology. 2020 Dec 5. doi: 10.1002/hep.31671.
    PubMed     Abstract available

    November 2020
  189. KNOOIHUIZEN SAI, Aday A, Lee WM
    Ketamine-Induced Sclerosing Cholangitis (KISC) in a Critically Ill Patient with COVID-19.
    Hepatology. 2020 Nov 23. doi: 10.1002/hep.31650.
    PubMed     Abstract available

  190. MOUSA OY, Juran BD, McCauley BM, Vesterhus MN, et al
    Bile Acid Profiles in Primary Sclerosing Cholangitis and their Ability to Predict Hepatic Decompensation.
    Hepatology. 2020 Nov 23. doi: 10.1002/hep.31652.
    PubMed     Abstract available

  191. KUNST RF, Verkade HJ, Oude Elferink RPJ, van de Graaf SFJ, et al
    Targeting the four pillars of enterohepatic bile salt cycling; lessons from genetics and pharmacology.
    Hepatology. 2020 Nov 22. doi: 10.1002/hep.31651.
    PubMed     Abstract available

  192. SATO K, Zhang W, Safarikia S, Isidan A, et al
    Organoids and spheroids as novel models for studying cholestatic liver injury and cholangiocarcinoma.
    Hepatology. 2020 Nov 22. doi: 10.1002/hep.31653.
    PubMed     Abstract available

  193. COLYN L, Barcena-Varela M, Alvarez-Sola G, Latasa MU, et al
    Dual targeting of G9a and DNMT1 for the treatment of experimental cholangiocarcinoma.
    Hepatology. 2020 Nov 22. doi: 10.1002/hep.31642.
    PubMed     Abstract available

  194. MEADOWS V, Francis H
    DCLK1 in Cholangiocarcinoma: Is this the biomarker and target we've been looking for?
    Hepatology. 2020 Nov 11. doi: 10.1002/hep.31630.
    PubMed     Abstract available

  195. SMETS L, Verbeek J, Korf H, van der Merwe S, et al
    Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate.
    Hepatology. 2020 Nov 3. doi: 10.1002/hep.31613.
    PubMed     Abstract available

    October 2020
  196. XU Y, Zhu Y, Hu S, Xu Y, et al
    Hepatocyte nuclear factor 4alpha prevents the steatosis-to-NASH progression by regulating p53 and bile acid signaling.
    Hepatology. 2020 Oct 23. doi: 10.1002/hep.31604.
    PubMed     Abstract available

  197. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Liver metastases of intrahepatic cholangiocarcinoma: implications for a potential new staging system.
    Hepatology. 2020 Oct 18. doi: 10.1002/hep.31598.
    PubMed     Abstract available

  198. BRAGELMANN J, Barahona Ponce C, Marcelain K, Roessler S, et al
    Epigenome-wide analysis of methylation changes in the sequence of gallstone disease, dysplasia, and gallbladder cancer.
    Hepatology. 2020 Oct 5. doi: 10.1002/hep.31585.
    PubMed     Abstract available

  199. KUNZMANN LK, Schoknecht T, Poch T, Henze L, et al
    Monocytes as Potential Mediators of Pathogen-Induced T-Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC).
    Hepatology. 2020;72:1310-1326.
    PubMed     Abstract available

    September 2020
  200. NEVI L, Di Matteo S, Carpino G, Zizzari I, et al
    DCLK1, a putative novel stem cell marker in human cholangiocarcinoma.
    Hepatology. 2020 Sep 25. doi: 10.1002/hep.31571.
    PubMed     Abstract available

  201. EATON JE, Welle CL, Bakhshi Z, Sheedy SP, et al
    Early cholangiocarcinoma detection with magnetic resonance imaging versus ultrasound in primary sclerosing cholangitis.
    Hepatology. 2020 Sep 25. doi: 10.1002/hep.31575.
    PubMed     Abstract available

    August 2020
  202. LEUNG KK, James PD, Jaberi A, Hirschfield GM, et al
    Esophageal Stenting as Bridge Therapy to Direct Intrahepatic Portocaval Shunt for Refractory Variceal Bleeding.
    Hepatology. 2020 Aug 11. doi: 10.1002/hep.31519.
    PubMed     Abstract available

    July 2020
  203. DU Y, Khandekar G, Llewellyn J, Polacheck W, et al
    Reply to letter to the editor: Comment on "a bile duct-on-a-chip with organ-level functions".
    Hepatology. 2020 Jul 21. doi: 10.1002/hep.31471.
    PubMed     Abstract available

  204. SCHULTHEISS C, Simnica D, Willscher E, Oberle A, et al
    Next-generation immunosequencing reveals pathological T cell architecture in autoimmune hepatitis.
    Hepatology. 2020 Jul 21. doi: 10.1002/hep.31473.
    PubMed     Abstract available

  205. LLEO A, Ma X, Gershwin ME, Invernizzi P, et al
    Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?
    Hepatology. 2020;72:359-360.

    April 2020
  206. ADAMS JM, Huppert KA, Castro EC, Lopez MF, et al
    Sox9 Is a Modifier of the Liver Disease Severity in a Mouse Model of Alagille Syndrome.
    Hepatology. 2020;71:1331-1349.
    PubMed     Abstract available

    March 2020
  207. LU ZN, Luo Q, Zhao LN, Shi Y, et al
    The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers.
    Hepatology. 2020;71:929-942.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Biliary Tract Diseases is free of charge.